Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study

Blood (2021) 138 (Supplement 1): 369.

https://doi.org/10.1182/blood-2021-150371

Published: 2021

Journal Articles

Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome

Lina Benajiba, MD PhD, Hetty E. Carraway, MD MBA, Nada Hamad, MB.BS, FRACP, FRCPA, Eytan M. Stein, MD, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Amy Burroughs, Scott Harris, Hayley Lane, Dorothy D. Nguyen, MD, Monic Stuart, MD MPH, Jesse Vargas, PhD, Alexandre Puissant, PhD, Kimberly Stegmaier, MD, Courtney D. DiNardo, MD MSCE

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-140636

Published: 2020

Journal Articles

A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

Francisco J. Hernandez-Ilizaliturri, MD, Ian W. Flinn, MD PhD, John Kuruvilla, MD, Sarit E Assouline, MD MSc, Matthew L. Ulrickson, MD, Beth A. Christian, MD, Daniel J. Landsburg, MD, Monic Stuart, MD MPH, Henry Lowman, PhD, Nancy Levin, PhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-142859

Published: 2020

Journal Articles

Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).

Mohamed Sorror, MD, MSc, Michael Maris, MD, Barry Storer, PhD, Brenda Sandmaier, MD, Monic Stuart, MD, Ute Hegenbart, MD, Edward Agura, MD, Thomas Chauncey, MD, Jose Leis, MD, PhD, Michael Pulsipher, MD, Peter McSweeney, MD, Jerry Radich, MD, James Wade, MD, Benedetto Bruno, MD, Amelia Langston, MD, Dietger Niederwieser, MD, Karl Blume, MD, Rainer Storb, MD, David Maloney, MD, PhD

Blood (2004) 104 (11): 2323.

https://doi.org/10.1182/blood.V104.11.2323.2323

Published: 2004

Journal Articles

Treatment for Acute Myelogenous Leukemia by Low Dose Irradiation Based Conditioning and Hematopoietic Cell Transplantation from Related and Unrelated Donors.

Dietger W. Niederwieser, Ute Hegenbart, MD, Brenda M. Sandmaier, MD, Michael B. Maris, MD, Monic Stuart, MD, Hildegard Greinix, MD, Catherine Cordonnier, Bernard Rio, MD, Alois Gratwohl, Thoralf Lange, MD, Wolfram Pönisch, MD, Leante Grommisch, MD, Barry Storer, MD, David Maloney, MD, Peter McSweeney, MD, Thomas Chauncey, MD, Ed Agura, MD, Karl Blume, Rainer Storb

Blood (2004) 104 (11): 3074.

https://doi.org/10.1182/blood.V104.11.3074.3074

Published: 2004

Journal Articles

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies

Michael B. Maris, Dietger Niederwieser, Brenda M. Sandmaier, Barry Storer, Monic Stuart, David Maloney, Effie Petersdorf, Peter McSweeney, Michael Pulsipher, Ann Woolfrey, Thomas Chauncey, Ed Agura, Shelly Heimfeld, John Slattery, Ute Hegenbart, Claudio Anasetti, Karl Blume, Rainer Storb

Blood (2003) 102 (6): 2021–2030.

https://doi.org/10.1182/blood-2003-02-0482

Published: 2003

NARROW

Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study

Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome

A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).

Treatment for Acute Myelogenous Leukemia by Low Dose Irradiation Based Conditioning and Hematopoietic Cell Transplantation from Related and Unrelated Donors.

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies

Email alerts

ASH Publications

American Society of Hematology

Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study

Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome

A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).

Treatment for Acute Myelogenous Leukemia by Low Dose Irradiation Based Conditioning and Hematopoietic Cell Transplantation from Related and Unrelated Donors.

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only